Moderna, Inc. - Common Stock (MRNA)
26.12
+0.00 (0.00%)
NASDAQ · Last Trade: Jun 6th, 9:43 AM EDT

U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health experts call a dichotomy in his approach to healthcare policy.
Via Benzinga · June 6, 2025

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via Chartmill · June 5, 2025

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.
Via Benzinga · June 5, 2025

Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Thursday. Discover the gap up and gap down stocks in the S&P500 index.
Via Chartmill · June 5, 2025

Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.
Via Chartmill · June 3, 2025

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Monday after the company announced its new COVID-19 vaccine secured clearance from the U.S. Food and Drug Administration (FDA) for seniors and at-risk individuals.
Via Benzinga · June 2, 2025

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.
Via Benzinga · June 2, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Via Chartmill · June 2, 2025

Investor sentiment on Moderna turned bearish over the weekend despite FDA approval of its new COVID-19 vaccine, mNEXSPIKE, which showed higher efficacy and a favorable safety profile.
Via Stocktwits · June 1, 2025

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Friday. Stay informed about the latest market trends.
Via Chartmill · May 30, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
Via Chartmill · May 29, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · May 29, 2025

The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, ending a key Biden-era pandemic preparedness initiative. The cancellation introduces uncertainty into the nation's defense strategy against H5N1 avian influenza despite positive clinical trial results.
Via Benzinga · May 29, 2025

The setback adds to recent regulatory delays, prompting cautious sentiment among retail investors expecting further downside.
Via Stocktwits · May 28, 2025
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.
Via Benzinga · May 27, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.
Via Chartmill · May 23, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · May 23, 2025
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
Via Chartmill · May 22, 2025
Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze
Via MarketBeat · May 22, 2025
The company previously guided to a longer timeline for its Covid/flu shot. But Wednesday's news introduces some data risk.
Via Investor's Business Daily · May 21, 2025
Moderna will resubmit the application later this year after data from its ongoing late-stage trial of its seasonal flu vaccine is available.
Via Stocktwits · May 21, 2025